LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

LLY

748.51

-1.17%↓

JNJ

152

+0.47%↑

UNH

302

+3.69%↑

ABBV

183.75

-0.11%↓

NVO

66.05

+2.66%↑

Search

Edwards Lifesciences Corp

Open

SectorGezondheidszorg

77.68 -0.31

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

77.13

Max

77.92

Belangrijke statistieken

By Trading Economics

Inkomsten

-28M

358M

Verkoop

27M

1.4B

K/W

Sectorgemiddelde

30.909

56.602

EPS

0.64

Winstmarge

25.342

Werknemers

15,800

EBITDA

-50M

434M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+3.71% upside

Dividenden

By Dow Jones

Volgende Winsten

23 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-882M

44B

Vorige openingsprijs

77.99

Vorige sluitingsprijs

77.68

Nieuwssentiment

By Acuity

73%

27%

349 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Edwards Lifesciences Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 jul 2024, 13:57 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences to Buy Innovalve for $300 Million

25 okt 2024, 09:10 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

25 okt 2024, 08:35 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

3 sep 2024, 20:38 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences: After Recent Accelerated Repurchase Agreement and August Buybacks Via 10b5-1 Agreement and Open Market Repurchases, Company Has $1.4B in Remaining Authorization

3 sep 2024, 20:37 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences Completes Sale of Critical Care Group to Becton Dickinson for $4.2B

3 sep 2024, 20:36 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences Authorizes $1.5B of Additional Share Repurchases

25 jul 2024, 09:02 UTC

Winsten
Populaire aandelen

Stocks to Watch Thursday: Ford, IBM, Chipotle, American Airlines -- WSJ

25 jul 2024, 08:40 UTC

Top Nieuws

These Stocks Are Moving the Most Today: Ford, Tesla, Alphabet, Nvidia, Super Micro, IBM, ServiceNow, Chipotle, and More -- Barrons.com

24 jul 2024, 20:17 UTC

Winsten

Edwards Lifesciences: Expects 2024 Edwards Sales Growth of 8% to 10% >EW

24 jul 2024, 20:15 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

24 jul 2024, 20:15 UTC

Winsten

Edwards Lifesciences 2Q Sales $1.39B >EW

24 jul 2024, 20:15 UTC

Winsten

Edwards Lifesciences 2Q Net $366.3M >EW

24 jul 2024, 20:15 UTC

Winsten

Edwards Lifesciences 2Q Adj EPS 70c >EW

24 jul 2024, 20:15 UTC

Winsten

Edwards Lifesciences 2Q EPS 61c >EW

15 jul 2024, 13:42 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences to Buy Innovalve for $300M

15 jul 2024, 13:01 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences: SAPIEN M3 Remains on Track to Become First Approved Transfemoral TMVR System in Europe by End of 2025 >EW

15 jul 2024, 13:01 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences: Acquisition Enhances TMVR Technologies to Address Large Unmet Structural Heart Patient Needs >EW

15 jul 2024, 13:00 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences to Acquire Innovalve Bio Medical Ltd., Early-Stage Transcatheter Mitral Valve Replacement Co >EW

15 jul 2024, 13:00 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences To Acquire Innovalve >EW

4 jun 2024, 17:26 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3 jun 2024, 13:26 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3 jun 2024, 12:25 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

3 jun 2024, 11:03 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2B in Cash

3 jun 2024, 10:40 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences To Sell Its Critical Care Product Group For $4.2 Billion To Becton Dickinson -- MarketWatch

3 jun 2024, 10:32 UTC

Acquisities, Fusies, Overnames

Becton Dickinson: Acquired Business Has About 4,500 Employees >BDX EW

3 jun 2024, 10:31 UTC

Acquisities, Fusies, Overnames

Becton Dickinson: Acquired Business Generated More Than $900 Million Revenue in 2023 >BDX

3 jun 2024, 10:31 UTC

Acquisities, Fusies, Overnames

Becton Dickinson: Deal Expands Portfolio of Smart Connected Care Solutions >BDX EW

3 jun 2024, 10:30 UTC

Acquisities, Fusies, Overnames

Becton Dickinson to Buy Edwards Lifesciences Critical Care Product Group for $4.2 Billion >BDX EW

3 jun 2024, 10:30 UTC

Acquisities, Fusies, Overnames

BD To Acquire Edwards Lifesciences' Critical Care Product Group For $4.2 Billion To Expand Smart Connected Care Solutions And Become An Advanced Monitoring Technology Leader >BDX EW

Peer Vergelijking

Prijswijziging

Edwards Lifesciences Corp Prognose

Koersdoel

By TipRanks

3.71% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 80.89 USD  3.71%

Hoogste 90 USD

Laagste 75 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Edwards Lifesciences Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

14 ratings

7

Buy

7

Hold

0

Sell

Technische score

By Trading Central

74.52 / 75.54Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

349 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.